Celebrating a breakthrough: FDA endorses encorafenib plus binimetinib alongside two companion diagnostics for BRAV600E mutant metastatic non-small cell lung cancer

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Benzimidazoles* / administration & dosage
• Carbamates* / administration & dosage
• Carcinoma, Non-Small-Cell Lung* / drug therapy
• Carcinoma, Non-Small-Cell Lung* / genetics
• Drug Approval
• Humans
• Lung Neoplasms* / drug therapy
• Lung Neoplasms* / genetics
• Mutation
• Proto-Oncogene Proteins B-raf* / genetics
• Sulfonamides* / administration & dosage
• United States
• United States Food and Drug Administration*